[Carboplatin-Vepeside in the treatment of non-small cell bronchial cancers. A phase II study].
Carboplatin, a derivative of cisplatin, has, when administered alone, a remission rate of almost 20 per cent. Forty-six patients were treated with the combination carboplatin/vepesid. Twenty-seven per cent of the patients experienced partial remission; in 41%, no change in the size of the tumour was observed. Neither alone nor in combination does carboplatin appear to show any nephrotoxicity or otoxicity, and its neurotoxic effect is only slight.
Heckmayr
M
M
Pneumologisch-Onkologische Abt., Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie, LVA Freie und Hansestadt Hamburg.
Gatzemeier
U
U
Hossfeld
D K
DK
Achterrath
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage
D009944:Organoplatinum Compounds; D005047:Etoposide; D016190:Carboplatin
Carboplatin-Vepesid in der Behandlung nicht kleinzelliger Bronchialkarzinome. Eine Phase II Studie.